Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25952563 | 0.92 | PAOX (0.50) | ALDH1A1GAAPAOXHTR1AHTR7 | |
| SCHEMBL24352087 | 0.85 | GNAI3 (0.49) | ALDH1A1PAOXHTR1AHTR7HSD11B1 | |
| SCHEMBL26005366 | 0.85 | GNAI3 (0.46) | ALDH1A1GAAPAOXHTR1AHTR7 | |
| SCHEMBL27342066 | 0.83 | NPC1 (0.53) | ALDH1A1PAOXKMT2APOLBHRH3 | |
| SCHEMBL26042830 | 0.82 | SIGMAR1 (0.52) | HRH3 | |
| SCHEMBL24352368 | 0.82 | GNAI3 (0.45) | ALDH1A1GAAPAOXHTR1AHTR7 | |
| SCHEMBL3766167 | 0.81 | SIGMAR1 (0.50) | ALDH1A1GAAKMT2ATSHRPOLB | |
| SCHEMBL24204316 | 0.81 | L3MBTL3 (0.47) | ALDH1A1KMT2ATSHRPOLBMAPT | |
| SCHEMBL4382097 | 0.77 | KMT2A (0.59) | ALDH1A1KMT2ATSHRMAPTHRH3 | |
| SCHEMBL4382883 | 0.77 | KMT2A (0.59) | ALDH1A1KMT2ATSHRMAPTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | ALDH1A1 3281/4885GAA 1842/4885PAOX 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.